These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18081705)

  • 1. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates.
    Gangat N; Strand J; Lasho TL; Finke CM; Knudson RA; Pardanani A; Li CY; Ketterling RP; Tefferi A
    Eur J Haematol; 2008 Mar; 80(3):197-200. PubMed ID: 18081705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
    Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
    Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].
    Roche-Lestienne C; Andrieux J
    Pathol Biol (Paris); 2007 Feb; 55(1):49-55. PubMed ID: 16901657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
    Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
    Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
    Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
    Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.
    Gangat N; Tefferi A; Thanarajasingam G; Patnaik M; Schwager S; Ketterling R; Wolanskyj AP
    Eur J Haematol; 2009 Jul; 83(1):17-21. PubMed ID: 19236446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
    Alvarez-Larrán A; Bellosillo B; Pereira A; Kerguelen A; Hernández-Boluda JC; Martínez-Avilés L; Fernández-Rodríguez C; Gómez M; Lombardía L; Angona A; Ancochea A; Senín A; Longarón R; Navarro B; Collado M; Besses C
    Am J Hematol; 2014 May; 89(5):517-23. PubMed ID: 24458835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
    Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
    Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic studies in polycythemia vera.
    Jarosová M; Indrák K; Dusek J; Kapustová M
    Neoplasma; 1988; 35(2):221-8. PubMed ID: 3374710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
    Cherry M; Khawandanah M; Zhao ZJ; Srour S; Ozer H; Selby G; Ghabache B; Al-Kali A
    Ann Hematol; 2015 Apr; 94(4):717-9. PubMed ID: 25380996
    [No Abstract]   [Full Text] [Related]  

  • 14. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.
    Tefferi A; Strand JJ; Lasho TL; Knudson RA; Finke CM; Gangat N; Pardanani A; Hanson CA; Ketterling RP
    Leukemia; 2007 Sep; 21(9):2074-5. PubMed ID: 17476276
    [No Abstract]   [Full Text] [Related]  

  • 15. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.
    Gianelli U; Iurlo A; Vener C; Moro A; Fermo E; Bianchi P; Graziani D; Radaelli F; Coggi G; Bosari S; Deliliers GL; Zanella A
    Am J Clin Pathol; 2008 Sep; 130(3):336-42. PubMed ID: 18701405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.
    Alvarez-Larrán A; Angona A; Ancochea A; García-Pallarols F; Fernández C; Longarón R; Bellosillo B; Besses C
    Eur J Haematol; 2016 Jan; 96(1):83-9. PubMed ID: 25810304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
    Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
    Hélias C; Struski S; Gervais C; Leymarie V; Mauvieux L; Herbrecht R; Lessard M
    Cancer Genet Cytogenet; 2008 Jan; 180(1):51-5. PubMed ID: 18068534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.